- Home
- AUTL vs EYPT Comparison
AUTL vs EYPT Comparison
Compare AUTL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- EYPT
- Stock Information
- Founded
- AUTL 2014
- EYPT 1987
- Country
- AUTL United Kingdom
- EYPT United States
- Employees
- AUTL N/A
- EYPT N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- AUTL Health Care
- EYPT Industrials
- Exchange
- AUTL Nasdaq
- EYPT Nasdaq
- Market Cap
- AUTL 625.4M
- EYPT 579.4M
- IPO Year
- AUTL 2018
- EYPT 2005
- Fundamental
- Price
- AUTL $2.25
- EYPT $9.48
- Analyst Decision
- AUTL Strong Buy
- EYPT Strong Buy
- Analyst Count
- AUTL 5
- EYPT 8
- Target Price
- AUTL $9.32
- EYPT $24.75
- AVG Volume (30 Days)
- AUTL 2.5M
- EYPT 821.1K
- Earning Date
- AUTL 08-07-2025
- EYPT 08-06-2025
- Dividend Yield
- AUTL N/A
- EYPT N/A
- EPS Growth
- AUTL N/A
- EYPT N/A
- EPS
- AUTL N/A
- EYPT N/A
- Revenue
- AUTL $9,011,000.00
- EYPT $56,042,000.00
- Revenue This Year
- AUTL $461.76
- EYPT N/A
- Revenue Next Year
- AUTL $112.66
- EYPT N/A
- P/E Ratio
- AUTL N/A
- EYPT N/A
- Revenue Growth
- AUTL N/A
- EYPT 12.04
- 52 Week Low
- AUTL $1.11
- EYPT $3.91
- 52 Week High
- AUTL $5.00
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- AUTL 69.32
- EYPT 72.76
- Support Level
- AUTL $1.98
- EYPT $7.94
- Resistance Level
- AUTL $2.10
- EYPT $10.77
- Average True Range (ATR)
- AUTL 0.13
- EYPT 0.74
- MACD
- AUTL -0.00
- EYPT 0.10
- Stochastic Oscillator
- AUTL 73.63
- EYPT 85.87
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.